By Fineline Cube 
China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc. for lenamilast (ITG-1052), an investigational PDE4 inhibitor. This collaboration grants Transpire Bio exclusive development, manufacturing, and commercialization rights to ITG-1052 in all territories except China.
Financial and Strategic Highlights
While the specific terms of the agreement remain undisclosed, it is reported that the upfront payment totals hundreds of millions of RMB. This significant investment underscores Transpire Bio’s commitment to expanding its innovative inhaled therapeutics pipeline, particularly in the area of respiratory inflammatory diseases.
Drug Profile and Pipeline Enhancement
Lenamilast, an investigational PDE4 inhibitor, represents a novel chemical entity that strengthens Transpire Bio’s portfolio. The drug has shown promise in the treatment of respiratory inflammatory conditions, aligning with Transpire Bio’s focus on developing cutting-edge therapies for unmet medical needs.-Fineline Info & Tech